Prospective Surveillance of Pediatric Invasive Group A Streptococcus Infection.


Journal

Journal of the Pediatric Infectious Diseases Society
ISSN: 2048-7207
Titre abrégé: J Pediatric Infect Dis Soc
Pays: England
ID NLM: 101586049

Informations de publication

Date de publication:
28 Mar 2019
Historique:
received: 02 06 2017
accepted: 15 10 2017
pubmed: 9 1 2018
medline: 2 5 2019
entrez: 9 1 2018
Statut: ppublish

Résumé

Invasive group A Streptococcus (GAS) disease has an incidence in high-income countries of 3 to 5 per 100000 per annum and a case-fatality ratio of 10% to 15%. Although these rates are comparable to those of invasive meningococcal disease in Australia before vaccine introduction, invasive GAS disease currently requires reporting in only 2 jurisdictions. Data were collected prospectively through active surveillance at the Royal Children's Hospital, Melbourne (October 2014 to September 2016). Isolation of GAS from a sterile site was required for inclusion. Comprehensive demographic and clinical data were collected, and emm typing was performed on all isolates. Disease was considered severe if the patient required inotropic support or mechanical ventilation. We recruited 28 patients. The median age of the patients was 3.5 years (range, 4 days to 11 years). Ten (36%) patients had severe disease. Fifteen (54%) children had presented to a medical practitioner for review in the 48 hours before their eventual admission, including 7 of the 10 patients with severe GAS infection. Complications 6 months after discharge persisted in 21% of the patients. emm1 was the most common emm type (29%). We found considerable short- and longer-term morbidity associated with pediatric invasive GAS disease in our study. Disease manifestations were frequently severe, and more than one-third of the patients required cardiorespiratory support. More than one-half of the patients attended a medical practitioner for assessment but were discharged in the 48-hour period before admission, which suggests that there might have been a window for earlier diagnosis. Our methodology was easy to implement as a surveillance system.

Sections du résumé

BACKGROUND BACKGROUND
Invasive group A Streptococcus (GAS) disease has an incidence in high-income countries of 3 to 5 per 100000 per annum and a case-fatality ratio of 10% to 15%. Although these rates are comparable to those of invasive meningococcal disease in Australia before vaccine introduction, invasive GAS disease currently requires reporting in only 2 jurisdictions.
METHODS METHODS
Data were collected prospectively through active surveillance at the Royal Children's Hospital, Melbourne (October 2014 to September 2016). Isolation of GAS from a sterile site was required for inclusion. Comprehensive demographic and clinical data were collected, and emm typing was performed on all isolates. Disease was considered severe if the patient required inotropic support or mechanical ventilation.
RESULTS RESULTS
We recruited 28 patients. The median age of the patients was 3.5 years (range, 4 days to 11 years). Ten (36%) patients had severe disease. Fifteen (54%) children had presented to a medical practitioner for review in the 48 hours before their eventual admission, including 7 of the 10 patients with severe GAS infection. Complications 6 months after discharge persisted in 21% of the patients. emm1 was the most common emm type (29%).
CONCLUSION CONCLUSIONS
We found considerable short- and longer-term morbidity associated with pediatric invasive GAS disease in our study. Disease manifestations were frequently severe, and more than one-third of the patients required cardiorespiratory support. More than one-half of the patients attended a medical practitioner for assessment but were discharged in the 48-hour period before admission, which suggests that there might have been a window for earlier diagnosis. Our methodology was easy to implement as a surveillance system.

Identifiants

pubmed: 29309631
pii: 4773390
doi: 10.1093/jpids/pix099
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

46-52

Informations de copyright

© The Author(s) 2017. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Natasha S Ching (NS)

Group A Streptococcus Research Group, Murdoch Children's Research Institute, Melbourne, Australia.
SAEFVIC, Murdoch Children's Research Institute, Melbourne, Australia.

Nigel Crawford (N)

Department of Paediatrics, Monash University, Melbourne, Australia.
Department of General Medicine, Royal Children's Hospital, Melbourne, Australia.
Molecular Bacteriology Laboratory, Université Libre de Bruxelles, Brussels, Belgium.

Alissa McMinn (A)

Department of Paediatrics, Monash University, Melbourne, Australia.

Ciara Baker (C)

Group A Streptococcus Research Group, Murdoch Children's Research Institute, Melbourne, Australia.
Department of General Medicine, Royal Children's Hospital, Melbourne, Australia.

Kristy Azzopardi (K)

Group A Streptococcus Research Group, Murdoch Children's Research Institute, Melbourne, Australia.

Kate Brownlee (K)

Department of Paediatrics, Monash University, Melbourne, Australia.

Donna Lee (D)

Department of Paediatrics, Monash University, Melbourne, Australia.

Margaret Gibson (M)

Department of Paediatrics, Monash University, Melbourne, Australia.

Pierre Smeesters (P)

Group A Streptococcus Research Group, Murdoch Children's Research Institute, Melbourne, Australia.
Department of General Medicine, Royal Children's Hospital, Melbourne, Australia.
Department of Microbiology, Royal Children's Hospital, Melbourne, Australia.
Department of Infection & Immunity, Monash Children's Hospital, Melbourne, Australia.

Gena Gonis (G)

Department of Pediatrics, Academic Children Hospital Queen Fabiola, Université Libre de Bruxelles, Brussels, Belgium.

Samar Ojaimi (S)

SAEFVIC, Murdoch Children's Research Institute, Melbourne, Australia.
Monash Centre for Health Research and Implementation, School of Public Health and Preventative Medicine, Monash University, Melbourne, Australia.

Jim Buttery (J)

Department of Paediatrics, Monash University, Melbourne, Australia.
SAEFVIC, Murdoch Children's Research Institute, Melbourne, Australia.
Department of Paediatrics, University of Melbourne, Melbourne, Australia.
Monash Centre for Health Research and Implementation, School of Public Health and Preventative Medicine, Monash University, Melbourne, Australia.

Andrew C Steer (AC)

Group A Streptococcus Research Group, Murdoch Children's Research Institute, Melbourne, Australia.
Department of General Medicine, Royal Children's Hospital, Melbourne, Australia.
Molecular Bacteriology Laboratory, Université Libre de Bruxelles, Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH